NCT03092895CompletedPhase 2
A Phase 2 Study of SHR-1210 (PD-1 Antibody) in Combination With Apatinib or Chemotherapy (FOLFOX4 or GEMOX) in Subjects With Advanced Primary Liver Cancer（PLC）or Biliary Tract Carcinoma (BTC)
Jiangsu HengRui Medicine Co., Ltd.7 sites in 1 country157 target enrollmentStarted: April 24, 2017Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 157
- Locations
- 7
- Primary Endpoint
- The Safety and Tolerability
Study Overview
Brief Summary
This an open-label，Non-Randominzed Phase 2 study to evaluate the Safety and Tolerability of SHR-1210 in combination with Apatinib or chemotherapy (FOLFOX4 or GEMOX regimen) in subjects with Advanced PLC.or BTC Participants with advanced PLC who failed or intolerable to prior systemic therapy will be treated with SHR-1210 plus Apatinib; Participants with advanced PLC or BTC who have never received prior systemic therapy will be treated with SHR-1210 plus FOLFOX4 or GEMOX regimen.
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 70 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histologically confirmed advanced PLC or advanced BTC (including bile duct carcinoma and gallbladder carcinoma) ; not suitable to surgery or local regional treatment; with at least one measurable lesion per RECIST 1.
- •Arm A:Failed or intolerable to at least one prior systemic treatment for advanced PLC. Arm B:No previous systemic treatment for advanced PLC or BTC
- •ECOG Performance Status of 0 or
- •Child-Pugh Class A or B with 7 points .
- •Life Expectancy of at least 12 weeks.
- •Has controlled infection by Hepatitis B Virus (HBV DNA<500 IU/ml) or Hepatitis C Virus.
- •Adequate organ function.
- •Male or female participants of childbearing potential must be willing to use an adequate method of contraception starting with the first dose of study drug through 60 days for female subjects and 120 days for male subjects after the last dose of study drug.
- •Patient has given written informed consent.
Exclusion Criteria
- •Known fibrolamellar HCC; Prior malignancy active with the previous 5 years except for locally curable cancers that have been apparently cured.
- •Known or occurrence of central nervous system (CNS) metastases.
- •Ascites with clinical symptoms.
- •Known or evidence of GI hemorrhage within the past 6 months.
- •Known or occurrence of hemorrhage/ thrombus.
- •Known or evidence of abdomen fistula, gastrointestinal perforation, or abdominal abscess within the past 2 months.
- •Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias.
- •Grade III~IV cardiac insufficiency, according to NYHA criteria or echocardiography check: LVEF<50%.
- •Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure > 140mmHg, diastolic blood pressure > 90 mmHg).
- •Factors to affect oral administration (such as patients unable to swallow oral medications, chronic diarrhea and ileus etc. situations evidently affect drug oral medication and absorption).
- •History of hepatic encephalopathy.
- •Known history of human immunodeficiency virus (HIV) infection.
- •Active infection or an unexplained fever > 38.5°C during screening visits.
- •Has received a live vaccine within 30 days.
- •Prior or planning to organ transplantation including liver transplantation.
- •Interstitial lung disease that is symptomatic or may interfere with the detection and management of suspected drug-related pulmonary toxicity.
- •Proteinuria≥ 2+ or 24 hours total urine protein > 1.0 g.
- •Active known, or suspected autoimmune disease.
- •Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily. prednisone equivalent, are permitted in the absence of active autoimmune disease
- •Any loco-regional therapy to liver (included but not limited: resection, radiotherapy, TAE, TACE, TAI, RFA or PEI) within 4 weeks prior to study.
- •Prior therapy with anti-PD-1 or other anti-PD-1/anti-PD-L1 immunotherapy.
- •Known history of hypersensitivity to monoclonal antibodies or any components of the study drugs.
- •Treatment with anti-coagulation therapy(Warfarin or heparin) or anti-platelet therapy(aspirin at dose≥300mg/day, clopidogrel at dose≥75mg/day).
- •Pregnant or breast-feeding women.
- •According to the investigator, other conditions that may lead to stop the research.
Arms & Interventions
SHR-1210+Apatinib(Arm A）
Experimental
Intervention: SHR-1210 (Biological)
SHR-1210+Apatinib(Arm A）
Experimental
Intervention: Apatinib (Drug)
SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）
Experimental
Intervention: SHR-1210 (Biological)
SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）
Experimental
Intervention: FOLFOX4 (Drug)
SHR-1210+FOLFOX4 or GEMOX regimen(Arm B）
Experimental
Intervention: GEMOX (Drug)
Outcomes
Primary Outcomes
The Safety and Tolerability
Time Frame: Up to approximately 4 years
The incidence of adverse events (AEs) and Serious adverse events (SAEs) assessed by NCI-CTCAE v4.03
Secondary Outcomes
- Objective Response Rate (ORR)(Up to approximately 4 years)
- Duration of Response (DoR)(Up to approximately 4 years)
- Disease Control Rate (DCR)(Up to approximately 4 years)
- Time to Progression (TTP)(Up to approximately 4 years)
- Overall Survival(Up to approximately 4 years)
- Time to Response (TTR)(Up to approximately 4 years)
- Progression-free Survival (PFS)(Up to approximately 4 years)
Investigators
Study Sites (7)
Loading locations...
Similar Trials
Terminated
Phase 2
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung CancerNSCLC Stage IVKRAS Gene MutationPD-1 AntibodyChemotherapy EffectNCT03777124Jiangsu HengRui Medicine Co., Ltd.25
Active, not recruiting
Phase 2
A Study to Evaluate SHR-1210 in Patients With Advanced or Metastatic NSCLCLung NeoplasmsCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms NecLung DiseaseRespiratory Tract DiseaseNeoplasm, BronchialCarcinoma, BronchogenicNCT03085069Jiangsu HengRui Medicine Co., Ltd.146
Unknown
Phase 2
A Phase II Study of SHR-1210 vs Placebo as Consolidation Chemotherapy After Radical Concurrent Chemoradiotherapy in Locally Advanced ESCCEsophageal Squamous Cell CarcinomaNCT03817658The First Affiliated Hospital of Zhengzhou University725
Unknown
Phase 2
PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral MelanomaMelanomaNCT03955354Peking University Cancer Hospital & Institute30
Active, not recruiting
Phase 2
SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction AdenocarcinomaGastric CancerNCT03950271Henan Cancer Hospital25